The immunological role of exosomes in allograft rejection remains unknown. We sought to determine whether exosomes are induced during lung allograft rejection and to define the antigenic compositions of HLA, lung-associated self-antigens (SAgs) and microRNAs (miRNAs). Exosomes were isolated from sera and bronchoalveolar lavage fluid from 30 lung transplant recipients (LTxRs) who were stable or who had acute rejection (AR) or bronchiolitis obliterans syndrome (BOS). Exosomes were defined by flow cytometry for CD63 and western blotting for annexin V SAgs, collagen V (Col-V) and Ka1 tubulin were examined by electron microscopy; miRNAs were profiled by a miRNA array. Donor HLA and SAgs were detected on exosomes from LTxRs with AR and BOS but not from stable LTxRs. Exosomes expressing Col-V were isolated from sera from LTxRs 3 mo before AR and 6 mo before BOS diagnosis, suggesting that exosomes with SAgs may be a noninvasive rejection biomarker. Exosomes isolated from LTxRs with AR or BOS also contained immunoregulatory miRNAs. We concluded that exosomes expressing donor HLA, SAgs and immunoregulatory miRNAs are present in the circulation and local site after human lung transplantation and play an important role in the immune pathogenesis of acute allograft rejection and BOS.
Introduction
Lung transplantation (LTx) is a treatment option for patients with end-stage lung disease such as idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and cystic fibrosis (1) (2) (3) . Although short-term survival has improved, acute rejection (AR) and bronchiolitis obliterans syndrome (BOS) remain major hurdles to long-term allograft function (4) . The mechanisms that lead to AR and BOS, namely, immune responses to mismatched donor HLA and non-HLA lung-associated self-antigens (SAgs), collagen V (Col-V) and Ka1 tubulin (Ka1T), also contribute to lung allograft rejection. Previous studies have demonstrated that de novo development of antibodies to donor-mismatched HLA (donor-specific antibodies [DSAs] ) and SAgs is associated with increased risk of AR and BOS after LTx (5) (6) (7) (8) . We have also demonstrated that DSA-induced changes to microRNAs (miRNAs) may prompt development of BOS (9) . Using an animal model of obliterative airway disease, we demonstrated that antibody administration to the SAg Col-V can induce immune responses not only to Col-V but also to another SAg, Ka1T and vice versa (10) . Furthermore, immune responses to SAgs can break self-tolerance, leading to airway inflammation and fibrosis in a syngeneic murine orthotopic LTx model (10) .
Exosomes are membrane vesicles (40-100 nm in diameter) produced by endocytic pathways and secreted into body fluids (11, 12) . They contain membrane, cytosolic proteins, messenger RNA (mRNA) and miRNA (13, 14) . MHC classes I and II have been detected on tumor cell exosomes and can induce antitumor immunity (15) . Exosomes from epithelial cells can induce activation of macrophages during lung inflammation, suggesting that exosomes can trigger airway inflammation (16) . The aim of this study was to determine whether exosomes are generated during lung allograft rejection and to define the origin and antigenic makeup of these exosomes, including the presence of SAgs. In this study, we demonstrated that exosomes containing SAgs are detectable in both the bronchoalveolar lavage (BAL) fluid and sera of lung transplant recipients (LTxRs) with AR and BOS but not in stable patients. This finding indicates that the exosomes originate from the transplanted organ after immune injury. We also demonstrated that mismatched donor HLA and SAgs are expressed on exosome surfaces and that exosomes contain miRNAs known to induce inflammation, endothelial activation, antibody-mediated chronic rejection and Th17 differentiation.
Methods

Patient population
In this case-control observational study, we identified 30 LTxRs who underwent bilateral LTx at Washington University/Barnes Hospital between 2012 and 2013. Ten of these patients developed BOS after LTx, 10 developed AR and 10 remained stable. On approval from the institutional review board at Washington University and informed consent from patients, sera and BAL fluid were collected at 1, 3, 6 and 12 mo after LTx and as required for clinical diagnosis. LTxRs with no evidence of rejection or microbial infection were designated as stable; AR and BOS were defined by International Society for Heart and Lung Transplantation criteria (17) .
Histopathology and C4d evaluation of biopsy showed that, of the 10 patients with AR, one patient had A1 rejection, eight had A2 rejection, and one had both A1 and A2B2 rejection. DSAs were present in three patients (30%) in the BOS group, in four patients (40%) in the AR group and in no patients in the stable group. There were no significant demographic differences among the groups (Table 1) . Immunotherapy protocol included cyclosporine, azathioprine and prednisone. Sera and BAL fluid were stored at À80°C.
Exosome isolation from BAL fluid by ultracentrifugation BAL fluid was centrifuged at 3000g for 30 min at 4°C and then at 10 000g for 30 min at 4°C. The supernatant was centrifuged at 100 000g for 70 min at 4°C. Exosome-containing pellets were washed with 1x phosphate-buffered saline (PBS) and centrifuged again at 100 000g for 70 min at 4°C. Exosome pellets were resuspended with 100 lL of 1x PBS buffer.
Exosome isolation from sera by precipitation
Exosomes from 1 mL of sera were isolated using the Total Exosome Isolation Reagent Kit (4478360, Invitrogen; Thermo Fisher Scientific, Waltham, MA) (18) . Sera were centrifuged at 2000g for 20 min at room temperature and then at 10 000g for 20 min at room temperature. Sera were then diluted with 0.5 volume of 1x PBS, and exosomes were precipitated with 0.2 volume of exosome precipitation reagent and centrifuged at 10 000g for 5 min at room temperature. Exosome pellets were solubilized with 1x PBS. Protein concentration of the exosomes was quantified using the Protein Assay Kit (23225, Pierce; Thermo Fisher Scientific). The mean concentration of exosomes isolated from LTxRs with BOS was 0.89 ng/lL (serum) and 0.33 ng/lL (BAL fluid). Mean concentration of exosomes isolated from LTxRs with AR was 0.34 ng/lL (serum) and 0.35 ng/lL (BAL fluid). Stable LTxRs also had exosomes with the CD63 marker, but neither sera nor BAL fluid contained the SAgs (serum 0.64 ng/lL, BAL fluid 0.45 ng/lL).
Exosome purification
Exosomes were purified with sucrose cushion (30%) ultracentrifugation to eliminate protein aggregates nonspecifically associated with exosomes (19, 20) . Exosomes isolated by the ultracentrifugation method were briefly resuspended in 25 mL of PBS. Next, 4 mL of sucrose cushions (Tris, sucrose and D 2 O solution) were added to the bottom of an SW 28 tube (Thermo Scientific, Rochester, NY); diluted exosomes were loaded without disturbing the interface. The tubes were centrifuged at 100 000g for 75 min at 4°C. Next, 3.5 mL of the Tris, sucrose and D 2 O cushion were collected without disturbing the interface, and the samples were made up to 60 mL with PBS. The exosome sample was centrifuged again for 70 min at 100 000g at 4°C, and the pelleted exosomes were resuspended with 100 lL of PBS for western blotting.
Western blotting
Total exosome protein from BAL and sera isolated from AR, BOS and stable LTxRs were analyzed for the exosome-specific marker annexin V and for lung-associated SAg Col-V, using immunoblot. Briefly, 10 lg of total exosome protein were denatured in laemmli buffer (Bio-Rad Laboratories, Hercules, CA) and boiled at 95°C for 5 min. Exosome protein samples were resolved in 12% Bis-Tris polyacrylamide gel and transferred to polyvinylidene fluoride membrane. The membrane was probed with exosome-specific marker protein annexin V using anti-annexin V antibody (ab14196; Abcam, Cambridge, UK) and antibodies to SAg Col-V (ab7046; Abcam). Goat antirabbit horseradish peroxidase was used as a secondary antibody (sc-2004; Santa Cruz Biotechnology, Dallas, TX). The blots were developed and exposed to x-ray films. Col-V band intensity was quantified using ImageJ software (National Institutes of Health, Bethesda, MD) and normalized with annexin V.
Transmission electron microscopy
Exosomes were negatively stained after absorption onto formvar and carbon-coated copper grids for 2 min. Grids were washed twice for 1 min each in distilled water and stained for 1 min with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA). Samples were viewed on JEOL 1200EX 
Flow cytometry
Serum exosomes were analyzed by a human CD63 isolation/detection kit (Life Technologies, Carlsbad, CA) with the use of CD63-coated DynaBeads (4.5 lM), according to the manufacturer's protocol. Exosomes bound to CD63 beads were briefly stained with PerCP/Cy5.5-conjugated anti-HLA A2 (343315, clone BB7.2; BioLegend, San Diego, CA) to track the donor-and allophycocyanin-conjugated anti-HLA A3 (clone GAP.A3, 17-5754; eBioscience, San Diego, CA) for recipient origin of the exosome. Baseline was established by staining the unbound CD63 DynaBeads and was compared with serum exosomes isolated from two LTxRs with BOS. Analysis of the presence of SAg (i.e. Col-V) on exosomes was evaluated by costaining the exosomes bound to CD63 DynaBeads with allophycocyanin-conjugated antiCol-V (AC16-0069-03; Abcore, Ramona, CA) and Exo-FITC (System Biosciences, Palo Alto, CA). Exosome surface marker analysis was performed using a BD FACSCANTO II system (BD Biosciences, San Jose, CA).
miRNA profiling
Exosomic miRNAs were isolated from pooled sera (one sample from each patient) using a mirVana miRNA isolation kit (Applied Biosystems, Foster City, CA). Global miRNA profiling was performed using an Affymetrix platform (GeneChip miRNA 3.0 array; Affymetrix, Santa Clara, CA). Differentially expressed exosomal miRNAs were analyzed using Partek Genomics Suite 6.6 software (Partek, St. Louis, MO), and the heat map was created using R statistics software (R Foundation for Statistical Computing, Vienna, Austria). The miRNA target prediction and pathway analysis was performed using DIANA-miRPath (http://microrna.gr/mirpath).
TaqMan miRNA real-time polymerase chain reaction
TaqMan miRNA real-time polymerase chain reaction (RT-PCR) was performed, as described previously (9) . Total RNA from exosomes isolated from sera and BAL fluid was briefly isolated using the mirVana miRNA isolation kit (Applied Biosystems). Reverse transcription was performed using the TaqMan miRNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR (qRT-PCR) was performed by TaqMan miRNA assays, as described previously (9).
Statistical analysis
The 10 patients in each group were selected based on sample availability and statistical test power. The efficiency of the sample pooling method was tested with efficient statistical test power (21, 22) . Exosome levels were compared between cohorts and correlated with clinical outcomes (Mann-Whitney two-tailed Student t-test). Statistical analysis was performed with GraphPad Prism (GraphPad Software, La Jolla, CA). Statistical data were expressed as mean plus or minus standard deviation. A p-value <0.05 was considered statistically significant.
Results
Exosomes containing SAg Col-V are induced by alloimmune responses after human LTx To determine whether exosomes generated from the transplanted organ are induced by alloimmune responses after LTx and to determine their presence both locally and in the circulation, exosomes were isolated from BAL fluid and sera of LTxRs who were stable (n = 10, no detectable DSA, rejection-free), LTxRs with AR (n = 10, four with DSAs and six without), and LTxRs with BOS (n = 10, three with DSAs and seven without). The isolated exosomes were pooled, and western blotting was performed using antibodies specific to Col-V. Exosomes derived from BOS patients' sera contained the SAg Col-V, but serum supernatant did not ( Figure S1A ). Furthermore, western blotting demonstrated that the purified exosomes from the sucrose cushion method contained exosome marker protein annexin V and SAg Col-V (Figure S1B) . Density metric analyses of Col-V band intensity were performed and normalized with annexin V intensity ( Figure S1C ). This clearly indicates that exosomes derived from LTxRs with BOS contained SAgs in exosome fraction purified by the sucrose cushion method, and the presence of Col-V did not result from protein aggregates.
Western blotting demonstrated SAg Col-V in exosomes isolated from LTxRs with AR and BOS and showed significantly less in the stable group or in healthy participants ( Figure 1A ). Similarly, a significant increase in exosomes containing Col-V was also noted in LTxRs with AR compared with the patients in the stable group (p = 0.001) ( Figure 1B) . These results clearly demonstrated that exosomes containing SAg Col-V could be a noninvasive biomarker of impending rejection.
SAgs Col-V and Ka1T were present on the surface of exosomes isolated from LTxRs with BOS and AR Exosomes derived from the sera of LTxRs with BOS and AR expressed SAgs, which were undetectable on the exosomes isolated from stable LTxRs (Figure 2A ). Similarly, exosomes isolated from BAL fluid from LTxRs with AR and BOS demonstrated expression of Col-V and Ka1T ( Figure 2B ), whereas exosomes isolated from stable LTxRs did not. Furthermore, to determine that serum-derived exosomes were of donor origin, we tar- expression on recipient HLA-A3. This confirms that the exosomes were released from the transplanted lung after alloimmune responses (Figure 3 ). The expression of SAgs and donor HLA on the surface of the exosomes isolated from LTxRs with BOS and AR suggests that exosome-mediated immune responses may contribute to AR and BOS pathogenesis.
Exosomes containing the SAg Col-V were demonstrable in the sera of LTxRs with AR and BOS before clinical diagnosis To determine whether exosomes were induced ahead of clinical diagnosis of AR and chronic rejection and present in the circulation, we isolated exosomes from the sera collected serially from three patients at 1, 3, and 6 mo after LTx. AR was clinically diagnosed in these patients at 1.9, 2.8, and 1.5 mo after LTx. Exosomes isolated from stable LTxRs at similar time points were used as the control. As shown in Figure 4 (A), exosomes containing Col-V were detected in the exosomes isolated from the sera just 1 mo after LTx in all patients with AR, much earlier than clinically diagnosed rejection (at 3 mo). Similarly, exosomes isolated from sera at 6, 12, and 18 mo from three LTxRs with BOS also contained Col-V that was detectable at 6 mo after LTx. BOS was clinically diagnosed in these patients at 19.8, 24.4, and 13.6 mo after LTx ( Figure 4B ). These results demonstrated that exosomes containing Col-V that are present in the sera of LTxRs with AR and BOS are detectable before clinical diagnosis of AR and chronic rejection. In contrast, the Col-V signal noted in stable LTxRs at 1 mo decreased to undetectable levels at 3 and 6 mo.
miRNAs were differentially expressed in exosomes from BOS and AR LTxRs compared with stable LTxRs To investigate the contribution of serum-derived exosomic miRNA in the immunopathogenesis of AR and BOS, we determined the miRNA of the exosomes isolated from pooled sera collected from each of the 30 patients. The graphical representation of heat maps indicates differentially expressed miRNAs, including lower and higher miRNA signals identified by gene chip miRNA analysis. The heat map represents relative fold change of differentially expressed miRNAs compared among LTxRs with AR and BOS and stable LTxRs ( Figure 5) . The global miRNA analysis demonstrated 123 detectable miRNAs (i.e. at least one pool with a positive detection signal) in exosomes from sera. Of these, 15 miRNAs were higher and 108 miRNAs were lower in LTxRs with AR compared with stable LTxRs (Table S1 ). In contrast, 44 miRNAs were higher and 79 miRNAs were lower in LTxRs with BOS compared with stable LTxRs (Table S1) .
We also performed comparative pathway analysis using DIANA-mirPath on differentially expressed miRNAs from AR and BOS exosomes. The results demonstrated that PI3K-Akt, Wnt, endocytosis, focal adhesion, ubiquitinmediated proteolysis, mitogen-activated protein kinase, TGF-b and mRNA surveillance pathways were significantly enriched in exosomic miRNAs from LTxRs with AR and BOS (p < 0.0001) (Figure 6 ). The differentially expressed miRNAs associated with various molecular pathways are summarized in Table S2 .
Global miRNA profiling showed high expression of miR-92a (involved in endothelial activation) and miR-182 (involved in inflammation) in LTxRs with AR. Similarly, differentially expressed miRNA in LTxRs with BOS demonstrated miR92a, miR-182 and the miRNAs involved in Th-17 activation (miR-155) and antibody-mediated rejection (miR-142-5p).
We carried out qRT-PCR with independent cohorts (Table S3) (Figure 7 ). Gene chip analysis of pooled samples did not show significant upregulation (Table S1 ). [Correction added after original publication 1 December 2016: The previous sentence was added.] This shows that miRNAs involved in inflammation and endothelial activation were significantly increased in LTxRs with AR and BOS and that the IL-17 pathway was activated in LTxRs with BOS.
Discussion
Exosomes are nanovesicles of endocytic origin, roughly 40-100 nm in diameter. Previous studies have demonstrated their role in intercellular communication (23) , cellto-cell communication (24) and pathogenesis of cancer and various kidney diseases (14, 25) . Exosomes can be released from different types of cells, including epithelial cells (26) , B cells (27, 28) , T cells (29) and macrophages (30) , all of which can be isolated from body fluids such as urine (31) , serum (32) , and BAL fluid (33) . The surface expression of tumor-specific protein and human epidermal growth factor receptor 2 derived from a human breast cancer cell line strongly supports the notion that tumor-derived exosomes can increase tumor cell proliferation (34) , but the role of exosomes in AR or chronic rejection after organ transplantation remains unknown. We attempted to define the role of exosomes as potential biomarkers in rejection after human LTx. LTx has the highest incidence of AR and chronic rejection of any organ, and LTxRs can be tested for the presence of exosomes not only in the circulation but also at the local site. In this study, exosomes isolated from BAL fluid and sera showed nanovesicular structure by EM and expression of exosome-specific surface marker CD63 in exosomes derived from LTxRs with AR and BOS (Figure S2) . The mean size of the vesicles isolated from the sera was 72 nm in diameter and 75 nm in those isolated from BAL fluid. SAg Col-V and exosome marker protein annexin V in a sucrose cushion demonstrated that Col-V is derived from exosomes. Furthermore, the presence of Col-V in exosome pellets, but not in the supernatant, confirmed that exosomes express Col-V.
A B
Exosomes isolated from LTxRs with AR and BOS contained SAgs (Figure 2 ) and donor HLA on their surface (Figure 3) , suggesting that the exosomes in rejection originate from the transplanted organ and express the SAgs Col-V and Ka1T. These data support the notion that both cellular and humoral rejection can induce formation of exosomes that are released into the circulation. We theorize that these exosomes may contribute to augmentation of immune responses against donor lungs because of the presence of both alloantigens and SAgs. Exosomes have also been reported to transfer functional MHCs to dendritic cells, which can express internalized protein and initiate antigen presentation (35, 36) . Preliminary results using flow cytometry demonstrated that exosomes from the sera of LTxRs with BOS showed donor HLA-A2 antigen but not recipient HLA-A3, indicating the donor origin of the exosomes following alloimmune responses ( Figure 3 ). The number of exosomes in the circulation that expressed donor HLA-A2 were low and may be due to the fact that isolated exosomes are the sum total of the exosomes released from different organs. Serial analysis of exosomes in the circulation demonstrated that exosomes containing Col-V were detectable 1 mo after LTx, 2 mo before clinical diagnosis of AR and 6 mo before clinical diagnosis of BOS.
The mechanism of exosome contribution to AR and chronic rejection after LTx has yet to be determined. Nevertheless, based on our previous findings that antibody-directed therapy and DSA clearance offer freedom from BOS (37) and that clearance of both DSAs and SAg antibodies offers greater freedom from BOS development (38) , it is possible that exosomes released from the donor lungs during rejection may support the immune responses that ultimately lead to BOS.
Our group documented that development of DSAs in LTxRs with BOS is associated with significant increases in miRNAs, which in turn induce TGF-b and B cell receptor signal pathways, ultimately leading to BOS pathogenesis (9) . Consequently, we hypothesize that the miRNAs in exosomes might be involved in regulation of the TGF-b signaling pathway, which induces airway inflammation and fibrosis in transplanted lungs. Differential expression of miRNAs observed in a global miRNA profile suggested that exosomes contain miRNAs that are involved in the B cell, T cell and TGF-b signaling pathways that regulate significant cellular processes and could contribute to immune-mediated development of AR and BOS ( Figure 6 and Table S2 ). In conclusion, these results demonstrated that exosomes are released into the circulation during AR and BOS and express not only the alloantigens of the donor but also SAgs. We also showed that Col-V-expressing exosomes can be detected before AR or BOS can be clinically diagnosed and that these exosomes originated from the transplanted lung. Exosomes isolated from LTxRs with AR and BOS also contained miRNAs known to be involved in immune regulation. Consequently, exosomes seem to play a significant role in augmenting immune responses to donor alloantigens and SAgs, ultimately leading to allograft rejection. 
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Additional Supporting Information may be found in the online version of this article. Table S1 , it has been updated, including the title, the body, and the legend. A clarifying statement directing readers to Table S1 has been added in the last paragraph of the Results section.] Table S2 : Comparative molecular pathway analysis using DIANA-mirPath on differentially expressed microRNAs from acute rejection or bronchiolitis obliterans syndrome exosomes. Table S3 : Lung transplant recipient demographics of replicative independent cohort for microRNA validation.
Figure S1: Exosomes isolated from the sera from LTxRs with BOS contained lung-associated SAg Col-V. Supernatant of serum samples after exosome isolation did not contain Col-V. Because analyses were done using both exosomes and supernatants, for this experiment, we used b-actin as the loading control (A). Results of western blot (B) and densitometric analysis of Col-V band intensity (C) showed lung-associated SAg Col-V in exosome fraction purified by the sucrose cushion method from three different LTxRs diagnosed with BOS. Col-V band intensity was normalized with the loading control annexin V. BOS, bronchiolitis obliterans syndrome; Col-V, collagen V; LTxR, lung transplant recipient; SAg, self-antigen. Figure S2 : Exosome validation. Exosomes isolated from serum samples were stained with 1% uranyl acetate. Vesicular structures ranging from 40 to 100 nm in diameter were detected using transmission EM (A).
Immunogold EM demonstrates exosome-specific surface marker CD63 in exosomes isolated from serum (B) and BAL (C). EM images are from one of the two experiments performed for serum and BAL fluid from lung transplant recipients classified as stable or diagnosed with acute rejection or bronchiolitis obliterans syndrome. BAL, bronchoalveolar lavage; EM, electron microscopy.
